Elsy Boglioli named as COO successor at Cellectis

French biotech company Cellectis (Euronext Paris: ALCLS) announced today that Dr Mathieu Simon is retiring as executive vice president and chief operating officer, effective immediately.

Following a smooth and successful transition over the last few months, Elsy Boglioli, EVP, strategy and corporate development, is named chief operating officer.

“Dr Simon has been incredibly instrumental in the strategic and operational direction of the therapeutic activities at Cellectis. Among his many achievements during his tenure, Dr Simon helped to fundamentally transform Cellectis from a research-oriented biotech company to a clinical-stage biopharma player. I warmly thank him for his service,” said Dr André Choulika, Cellectis’ chief executive, adding: “I look forward to Elsy Boglioli’s leadership as our new chief operating officer as we enter the next phase of the Company’s development.”